Overview

Kratom (Mitragyna speciosa) is a tropical evergreen tree in the coffee family (Rubiaceae) native to Southeast Asia, where its leaves have been used for centuries as a traditional medicine and stimulant by agricultural workers. The primary bioactive alkaloids — mitragynine (comprising 60–66% of total alkaloid content) and 7-hydroxymitragynine (a minor but highly potent constituent) — exhibit complex, dose-dependent pharmacology. At low doses (1–5 g of dried leaf), kratom acts primarily as a stimulant through adrenergic and serotonergic mechanisms, increasing energy, alertness, and sociability. At higher doses (5–15 g), opioid receptor agonism predominates, producing analgesia, sedation, and euphoria through mu- and delta-opioid receptor activation.

The dual pharmacological nature of kratom has generated significant clinical interest and controversy. Mitragynine functions as a partial agonist at mu-opioid receptors with additional activity at alpha-2 adrenergic, serotonin (5-HT2A), and dopamine (D2) receptors, creating a pharmacological profile distinct from classical opioids. Importantly, kratom alkaloids demonstrate "biased agonism" at opioid receptors, preferentially activating G-protein signaling over beta-arrestin recruitment — a property associated with reduced respiratory depression risk compared to morphine. This has positioned kratom as a subject of research for opioid use disorder management, with observational studies from Southeast Asia and Western self-report data suggesting utility in opioid withdrawal and chronic pain. However, dependence and withdrawal syndromes have been well-documented with regular use.

The regulatory status of kratom remains contentious globally. The FDA has expressed concerns about safety, citing reports of adverse events and deaths (typically involving polysubstance use), while the American Kratom Association advocates for regulated access. From a harm-reduction perspective, kratom occupies a complex niche between traditional botanicals like kava and prescription opioid therapy. Users exploring botanical approaches to mood and pain management may also consider kanna for serotonergic mood support or passionflower and valerian-root for anxiolytic effects with better-established safety profiles. Clinical supervision is strongly recommended for anyone using kratom, particularly those with a history of substance use disorders.

Mechanism of Action

Kratom (Mitragyna speciosa) contains over 40 structurally related indole alkaloids, with mitragynine comprising approximately 60-70% of total alkaloid content and 7-hydroxymitragynine present in smaller quantities but with significantly higher potency. These alkaloids exert their effects primarily through the opioid receptor system, functioning as atypical opioid ligands with a unique pharmacological profile. Mitragynine acts as a partial agonist at mu-opioid receptors (MOR) and competitive antagonist at delta-opioid receptors (DOR) and kappa-opioid receptors (KOR). 7-hydroxymitragynine is a more potent MOR agonist with approximately 13-fold greater potency than morphine at this receptor. Crucially, mitragynine and its analogs demonstrate biased agonism at MOR, preferentially activating G-protein signaling pathways over beta-arrestin-2 recruitment, which is hypothesized to produce analgesia with a reduced side effect profile compared to classical opioids regarding respiratory depression and constipation.

Beyond opioid receptors, kratom alkaloids interact with adrenergic receptors (alpha-2 adrenergic agonism by mitragynine contributes to analgesic and sedative effects), serotonergic receptors (5-HT2A and 5-HT2C receptor interactions contribute to mood-altering and potential psychedelic-adjacent effects at high doses), and dopaminergic pathways. Mitragynine inhibits neuronal firing through blockade of voltage-gated calcium channels and activates descending noradrenergic and serotonergic pain inhibition pathways. At lower doses, kratom's stimulant effects are attributed to adrenergic receptor activation and possible dopamine modulation, producing increased alertness, energy, and sociability. At higher doses, the mu-opioid partial agonism predominates, producing analgesia, sedation, and euphoria. This dose-dependent shift from stimulant to sedative effects reflects the differential receptor engagement and binding kinetics of the alkaloid mixture.

Mitragynine is extensively metabolized by hepatic cytochrome P450 enzymes (primarily CYP3A4 and CYP2D6) into several active metabolites, including 7-hydroxymitragynine, which may contribute to the in vivo pharmacological effects beyond what the parent compound alone would produce. Other kratom alkaloids including paynantheine (a smooth muscle relaxant acting on opioid receptors), speciogynine (smooth muscle relaxant), and corynantheidine (MOR competitive antagonist) modulate the overall pharmacological profile of the crude extract. The combined action of multiple alkaloids on opioid, adrenergic, serotonergic, and dopaminergic systems, along with ion channel modulation, produces kratom's complex pharmacology that spans analgesia, mood elevation, anxiolysis, stimulation, and sedation depending on dose and alkaloid composition.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Kratom (Mitragyna speciosa)

Common Side Effects

• Nausea and vomiting (very common, especially at higher doses or in new users)
• Constipation (opioid-like effect on gastrointestinal motility; frequent with regular use)
• Drowsiness and sedation at moderate-to-high doses (>5 g powder)
• Stimulant effects at low doses (1–3 g): agitation, anxiety, insomnia, tachycardia
• Dry mouth, increased urination, and appetite suppression
• Sweating, itching, and facial flushing
• Dizziness and loss of coordination

Serious Adverse Effects

• Dependence and withdrawal: chronic use produces opioid-like physical dependence; withdrawal symptoms include muscle aches, irritability, insomnia, diarrhea, runny nose, and intense cravings (onset 12–48 hours after last dose)
• Hepatotoxicity: multiple case reports of cholestatic liver injury and acute liver failure, some requiring transplantation; mechanism unclear but may involve mitragynine metabolites
• Seizures: reported particularly with high doses or adulterated products
• Respiratory depression: rare but documented, especially when combined with opioids, benzodiazepines, or alcohol
• Cardiac effects: QT prolongation, tachycardia, and rare cases of cardiac arrest at high doses
• Deaths: FDA has linked >90 deaths to kratom-containing products, often involving polysubstance use
• Neonatal abstinence syndrome: reported in infants born to mothers using kratom during pregnancy

Contraindications

• History of substance use disorder (high abuse potential)
• Liver disease or hepatic impairment
• Cardiac arrhythmias or QT prolongation
• Concurrent opioid, benzodiazepine, or sedative use
• Seizure disorders (lowers seizure threshold)
• Pregnancy and lactation (neonatal abstinence syndrome risk)
• Psychiatric disorders (may exacerbate psychosis, anxiety, or depression)

Drug Interactions

• Opioids (morphine, oxycodone, fentanyl): HIGH RISK — additive respiratory depression and sedation; competitive mu-opioid receptor binding
• Benzodiazepines and CNS depressants: profound sedation and respiratory depression
• CYP3A4 and CYP2D6 inhibitors/substrates: mitragynine is metabolized by these enzymes; co-administration may increase toxicity
• MAO inhibitors: theoretical risk of serotonergic crisis (mitragynine has weak serotonergic activity)
• Anticoagulants: isolated reports of altered coagulation parameters
• Antidepressants (SSRIs/SNRIs): additive serotonergic effects at high kratom doses

Population-Specific Considerations

• Pregnancy: contraindicated; associated with neonatal abstinence syndrome, low birth weight, and developmental concerns
• Lactation: mitragynine is excreted in breast milk; contraindicated
• Children/Adolescents: strictly not recommended; developing brains are more vulnerable to opioid-like effects
• Elderly: increased sensitivity to sedation, falls, constipation, and hepatotoxicity
• Regulatory status: classified as a controlled substance in several countries and US states; FDA has not approved kratom for any medical use; DEA has listed it as a Drug and Chemical of Concern

Pharmacokinetic Profile